Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Cost of Revenue · Q2 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q2 FY2026 cost of revenue was $149.33K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.54M. Over 3 fiscal years it compounded at +54.6% a year.
Context
- Cost of revenue amounted to 53.5% of revenue in FY2025.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $149.33K or moves back toward the trailing-twelve-month quarterly average of $383.82K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 756.33K USD
- Year-over-year change
- +564.3%
- 4-year CAGR
- +30.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 756.33K | +564.3% |
| FY2024 | 2024-09-30 | 113.86K | +157.7% |
| FY2023 | 2023-09-30 | 44.19K | -78.4% |
| FY2022 | 2022-09-30 | 204.69K | -21.9% |
| FY2021 | 2021-09-30 | 262.14K | — |
Cost of Revenue vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 cost of revenue of $1.54M is the 3rd highest of the 9 companies compared; the peer median is $271.51K.
- Its year-over-year change of +977.1% is the 3rd highest of 5, against a peer median of +8790.4%.
- Cost of revenue amounts to 460.9% of revenue for OTLK, versus a peer median of 13.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.86M | — | — | — | |
| LTM Jun 2026 | $2.85M | +242.5% | -13.3% | 13.6% | |
| LTM Mar 2026 | $1.54M | +977.1% | +54.6% | 460.9% | |
| LTM Mar 2026 | $1.44M | +35950.0% | +401.7% | 62.9% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $362.39K | +17280.8% | +666.9% | — |
| LTM Mar 2026 | $180.63K | +300.0% | — | 12.8% | |
| LTM Mar 2026 | $79K | — | — | 0.2% | |
| LTM Mar 2026 | $79K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding OTLK) | $271.51K | +8790.4% | +401.7% | 13.2% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K |
| Gross Profit | (262.14K) | (204.69K) | (44.19K) | (113.86K) | 657.21K |
| Gross Margin | — | — | — | — | 46.5% |
| Research & Development | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T |
| Selling, General & Admin | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M |
| Operating Expenses | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| EBITDA | (51.51M) | (64.36M) | (57.38M) | (72.09M) | (63.58M) |
| EBITDA Margin | — | — | — | — | -4497.7% |
| Operating Income | (51.73M) | (63.07M) | (53.13M) | (71.7M) | (67.06M) |
| Operating Margin | — | — | — | — | -4744.3% |
| Interest Income | 0 | 0 | 0 | 906.15K | 89.74K |
| Interest Expense | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K |
| Other Income / Expenses | (1.43M) | (2.98M) | (5.85M) | (3.66M) | 3.08M |
| Income Before Tax | (53.16M) | (66.05M) | (58.98M) | (75.36M) | (63.98M) |
| Pre-Tax Margin | — | — | — | — | -4526.0% |
| Income Tax Expense | 2K | 2.8K | 2.8K | 2.8K | (1.55M) |
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Net Margin | — | — | — | — | -4416.2% |
| EPS (Basic) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| EPS (Diluted) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| Weighted Avg Shares | 7.63M | 10.6M | 12.51M | 18.55M | 34.8M |
| Weighted Avg Shares (Diluted) | 7.63M | 10.6M | 12.51M | 18.55M | 25.48M |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.